 |
53 Diseases |  |
489 Trials |
|
489 Trials |  |
8953 News |  |
| «12...6667686970717273747576...123124» |
- |||| lenvatinib / Generic mfg.
LAUNCH trial: Lenvatinib +/- TACE for BCLC C disease. Improved OS and PFS for Len + TACE group #GI22 (Twitter) - Jan 21, 2022
- |||||| lenvatinib / Generic mfg.
Clinical, P3 data: ABS# 380: Lenvatinib + TACE as 1st treatment of advanced #hepatocellular #cancer: A phase 3, multicenter, randomized controlled trial (N=338) resulting in improved OS, PFS, and RR. #GI22 @ASCOPost @ASCO #clinicaltrials #cancerresearch @AHPBA #HCC (Twitter) - Jan 21, 2022
- |||| lenvatinib / Generic mfg.
Clinical: I feel like I need to see a TACE-only group to prove you couldn't get a 40% response rate in this trial's patient population, without the lenvatinib part. #GI22 (Twitter) - Jan 21, 2022
- ||| lenvatinib / Generic mfg.
Speaking of considering novel treatment strategies: TACE starts 1 day after lenvatinib? That doesn't sound like it allows any reasonable time for a TKI to work and 'prime' the tumor to be most susceptible; and perhaps sequentially would be better to TACE first? #GI22 (Twitter) - Jan 21, 2022
- | Nexavar (sorafenib) / Bayer, Amgen
Biomarker, Journal: ST6GAL1 is a novel serum biomarker for lenvatinib-susceptible FGF19-driven hepatocellular carcinoma. (Pubmed Central) - Jan 21, 2022
serum ST6GAL may be a novel biomarker that identifies lenvatinib-susceptible FGF19-driven HCC.
- | lenvatinib / Generic mfg.
Journal: Bi/Se-Based Nanotherapeutics Sensitize CT Image-Guided Stereotactic Body Radiotherapy through Reprogramming the Microenvironment of Hepatocellular Carcinoma. (Pubmed Central) - Jan 21, 2022
After loading Lenvatinib (Len), the obtained Bi/Se-Len NPs had excellent performance in reversing hypoxia and the immune suppression status of HCC...Comprehensive tests and histological stains revealed that Bi/Se-Len NPs could reshape and normalize tumor blood vessels, reduce the hypoxic situation of the tumor, and upregulate tumor-infiltrating CD4 and CD8 T lymphocytes around the tumors. Our work highlights an excellent proposal of Bi/Se-Len NPs as theranostic nanoparticles for image-guided HCC radiotherapy.
- | lenvatinib / Generic mfg.
Journal: The Knockdown of Nrf2 Suppressed Tumor Growth and Increased the Sensitivity to Lenvatinib in Anaplastic Thyroid Cancer. (Pubmed Central) - Jan 21, 2022
Lastly, knockdown of Nrf2 increased the sensitivity of anaplastic thyroid cancer cells to lenvatinib. As knockdown of Nrf2 reduced the metastatic and invasive ability of anaplastic thyroid cancer cells by inhibiting the Notch 1 signaling pathway and increased the cancer cell sensitivity to lenvatinib, Nrf2 could be a promising therapeutic target for patients with anaplastic thyroid cancer.
- ||| Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Clinical, Clinical data, Retrospective data, Review, Journal, Adverse events: Clinical Outcomes and Adverse Events after First-Line Treatment in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis. (Pubmed Central) - Jan 21, 2022
N+C may provide the most favorable OS, L+P the most favorable PFS and ORRs, while N+I the lowest toxicity. Population differences may potentially undermine the generalizability and the robustness of findings.
- ||||| Keytruda (pembrolizumab) / Merck (MSD), lenvatinib / Generic mfg.
Clinical: Lenvatinib plus Pembrolizumab for Endometrial Cancer- Another win for this combo, the Ph 1 of which was led by our own Dr. Matthew Taylor, Director of Developmental Cancer Therapeutics Lab @ChilesResearch & Thyroid Program @ProvHealth https://t.co/eUjHlKaaiB (Twitter) - Jan 21, 2022
- || Nexavar (sorafenib) / Bayer, Amgen
Clinical, Journal: A Case of Advanced Hepatocellular Carcinoma That Caused Rapid Re-Growth Due to Lenvatinib Withdrawal (Pubmed Central) - Jan 21, 2022
Although the use of lenvatinib may results in tumor shrinkage, suggesting that prolonged drug withdrawal may make disease management difficult. It is important to manage adverse events and minimize days of drug withdrawal by reducing the dose and systematically discontinuing the drug.
- || Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Clinical, Journal: A Case of Combined Hepatocellular Carcinoma and Cholangiocarcinoma with Multidisciplinary Treatment Including Lenvatinib (Pubmed Central) - Jan 21, 2022
Chemotherapy(gemcitabine, cisplatin plus S-1: GCS)was performed for intrahepatic cholangiocarcinoma(r/o combined hepatocellular carcinoma and cholangiocarcinoma)...Tumor thrombus was vitrified and necrotic. After hepatectomy, administration of lenvatinib was continued for the residual lesion, and no significant tumor growth was observed.
- |||| Keytruda (pembrolizumab) / Merck (MSD), lenvatinib / Generic mfg.
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer- Another win for this combo, the phase 1 of which was led by our own Dr. Matthew Taylor, Developmental Cancer Therapeutics Lab Director & Med Dir of our Thyroid Program @ChilesResearch https://t.co/eUjHlKaaiB (Twitter) - Jan 21, 2022
- || lenvatinib / Generic mfg.
Clinical, Journal: A Case of Laparoscopic Resection Using the ICG Fluorescence for Peritoneal Disseminations of Hepatocellular Carcinoma (Pubmed Central) - Jan 21, 2022
Treatment with lenvatinib was started due to multiple liver recurrences and peritoneal disseminations...Disseminated lesions could be easily detected with intraoperative fluorescence imaging, and we could completely resect disseminated lesions. The ICG fluorescence could be considered to be useful in laparoscopic resection for peritoneal dissemination of HCC.
- ||| Keytruda (pembrolizumab) / Merck (MSD), lenvatinib / Generic mfg.
Lenva Pembro = Always works in solid tumors . 🙂 (Twitter) - Jan 21, 2022
- ||| Keytruda (pembrolizumab) / Merck (MSD), lenvatinib / Generic mfg.
Clinical: I'd like to see pembro/len vs pembro/placebo (Twitter) - Jan 20, 2022
- ||| Keytruda (pembrolizumab) / Merck (MSD), lenvatinib / Generic mfg.
Se acaba de publicar en @NEJM el ensayo clínico fase III que establece un nuevo tratamiento estándar para la 2ª línea de cáncer de endometrio, para las pacientes con tumores pMMR: pembrolizumab-lenvatinib. Pero ojo, su elevada toxicidad no lo hace apto para todas (Twitter) - Jan 20, 2022
- ||| Keytruda (pembrolizumab) / Merck (MSD), lenvatinib / Generic mfg.
Endometria ca:The median OS ⬆️ with lenvatinib+ pembro than with chemo (pMMR: 17.4 vs. 12 mos; HR for death, 0.68; 95% CI, 0.56 to 0.84; P<0.001; overall: 18.3 vs. 11.4 mos; HR, 0.62; 95% CI, 0.51 to 0.75; P<0.001). @NEJM @sloan_kettering https://t.co/9nrTi6JGUc (Twitter) - Jan 20, 2022
- | lenvatinib / Generic mfg.
Journal: Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer. (Pubmed Central) - Jan 19, 2022
In this real-life clinical experience, lenvatinib showed interesting results as salvage therapy in patients with advanced progressive metastatic MTC patients. Its usefulness could be effective in patients without any other available treatment, because previously used or unsuitable, especially with negative RET status with no access to the new highly selective targeted therapies.
- ||| Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Retrospective data, Journal, Adverse events: Cardiovascular Toxicities of Antiangiogenic Tyrosine Kinase Inhibitors: A Retrospective, Pharmacovigilance Study. (Pubmed Central) - Jan 19, 2022
Hypertension, aortic dissections, and pericardial diseases had the highest reporting odds ratios. While the association of VEGFR-TKIs with hypertension is well established, pericardial diseases were not observed to date, and aortic dissection was reported in a small case series.
- ||| lenvatinib / Generic mfg.
#Eisai To Present Abstracts On #Lenvatinib At #ASCOGI22 https://t.co/JtTCAceAys (Twitter) - Jan 19, 2022
- || Retrospective data, Review, Journal: Evidence-based management of HCC: Systematic review and meta-analysis of randomized controlled trials (2002-2020). (Pubmed Central) - Jan 18, 2022
Among 49 high-quality RCTs conducted in HCC during 2002-2020, nine resulted in positive results. A meta-analysis of systemic therapies suggest that immunotherapies may be less effective in non-viral etiologies.
- | lenvatinib / Generic mfg.
Journal: Liver Function and Bleeding Complications Associated with Lenvatinib. (Pubmed Central) - Jan 15, 2022
A meta-analysis of systemic therapies suggest that immunotherapies may be less effective in non-viral etiologies. No abstract available
- || lenvatinib / Generic mfg.
Clinical, Journal, Real-world evidence: Lenvatinib as First-line Treatment of Hepatocellular Carcinoma in Patients with Impaired Liver Function in Advanced Liver Cirrhosis: Real World Data and Experience of a Tertiary Hepatobiliary Center. (Pubmed Central) - Jan 15, 2022
No abstract available Tolerability and toxicity of lenvatinib are similar in patients withChild-Pugh class A and class B LC, but patients with less impaired liver function have a better survival benefit.
- | lenvatinib / Generic mfg.
Journal, PD(L)-1 Biomarker, IO biomarker: Lenvatinib Targets FGFR4 to Enhance Antitumor Immune Response of Anti-PD-1 in Hepatocellular Carcinoma. (Pubmed Central) - Jan 15, 2022
Lenvatinib reduced tumor PD-L1 level and Treg differentiation to improve anti-PD-1 efficacy by blocking FGFR4. Levels of FGFR4 expression and Tregs infiltration in tumor could serve as biomarkers for screening HCC patients with lenvatinib plus anti-PD-1 combination therapy.
- | lenvatinib / Generic mfg.
Preclinical, Journal, Patient Enrichment, PD(L)-1 Biomarker, IO biomarker: Immunomodulatory effects of lenvatinib plus anti-PD1 in mice and rationale for patient enrichment in hepatocellular carcinoma. (Pubmed Central) - Jan 14, 2022
Lenvatinib plus anti-PD1 exerted unique immunomodulatory effects through activation of immune pathways, reduction of T cell infiltrate, and inhibition of TGFß signaling. A gene signature enabled the identification of ~20% of human HCCs that, while non-responding to single agents, could benefit from the proposed combination.
- || Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS, Nexavar (sorafenib) / Bayer, Amgen
Clinical, Review, Journal, Checkpoint inhibition: Comparative safety and efficacy of molecular-targeted drugs, immune checkpoint inhibitors, hepatic arterial infusion chemotherapy and their combinations in advanced hepatocellular carcinoma: findings from advances in landmark trials. (Pubmed Central) - Jan 14, 2022
Here, we present preliminary evidence for the comparative safety and efficacy of existing MTDs, ICIs, HAIC and their combinations in AHCC, which indicated that HAIC-oxaliplatin monotherapy has acceptable toxicity and efficacy and could be the cornerstone for future combination of systemic treatments in AHCC. Our findings might provide insight into the future design of multidisciplinary treatments in AHCC.
- | lenvatinib / Generic mfg.
Biomarker, Retrospective data, Journal, Real-world evidence: Efficacy and Safety of Lenvatinib for Patients With Advanced Hepatocellular Carcinoma: A Retrospective, Real-world Study Conducted in Japan. (Pubmed Central) - Jan 14, 2022
Lenvatinib is safe and effective for patients, whether or not they satisfy REFLECT criteria. The result warrants replication in a larger study.
- | lenvatinib / Generic mfg.
Biomarker, Journal: circRNA circMED27 acts as a prognostic factor and mediator to promote lenvatinib resistance of hepatocellular carcinoma. (Pubmed Central) - Jan 14, 2022
Our mechanistic investigations revealed that circMED27 functions as a competing endogenous RNA (ceRNA) for miR-655-3p to upregulate ubiquitin-specific peptidase 28 (USP28) expression. Thus, we are led to conclude that circMED27 acts as a potential therapeutic target for HCC patients receiving lenvatinib therapy and may represent a promising molecular biomarker for forecasting lenvatinib-resistant HCC.
- | lenvatinib / Generic mfg.
Journal: Paraneoplastic Polyarthritis in Hepatocellular Carcinoma Treated with Lenvatinib. (Pubmed Central) - Jan 13, 2022
The patient was started on prednisone, celecoxib and opioids with minimal improvement in pain and function. Paraneoplastic arthritis was suspected.
- | Opsumit (macitentan) / Nippon Shinyaku, J&J
Journal: Successful Management with Dual Therapy of Lenvatinib and Macitentan for Hepatocellular Carcinoma with Portopulmonary Hypertension. (Pubmed Central) - Jan 13, 2022
Certain drugs, including dasatinib, a tyrosine kinase inhibitor (TKI) for chronic myelogenous leukemia, have been identified as risk factors for the development of PAH. However, although TKIs, such as lenvatinib, have been widely used for the treatment of HCC, no reports have demonstrated the association of TKIs for HCC with PAH.
- | Nexavar (sorafenib) / Bayer, Amgen
Retrospective data, Journal: Advanced hepatocellular carcinoma treated by transcatheter arterial chemoembolization with drug-eluting beads plus lenvatinib versus sorafenib, a propensity score matching retrospective study. (Pubmed Central) - Jan 13, 2022
The patients in DEB-TACE+LEN group had a significantly lower incidence of hand-foot skin reaction (32.0% vs. 49.0%; P=0.048), but a higher incidence of proteinuria (26.0% vs. 10.0%; P=0.010) than that in the DEB-TACE+SOR group. In conclusion, DEB-TACE+LEN conferred better ORR, OS and TTP than did DEB-TACE+SOR in patients with advanced HCC, especially those with PVTT and FGF21 amplification, with acceptable AEs; thus making it a superior treatment modality for these patients.
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Combination therapy: A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma (clinicaltrials.gov) - Jan 13, 2022
P2, N=72, Active, not recruiting, Sponsor: Eisai Inc.
In conclusion, DEB-TACE+LEN conferred better ORR, OS and TTP than did DEB-TACE+SOR in patients with advanced HCC, especially those with PVTT and FGF21 amplification, with acceptable AEs; thus making it a superior treatment modality for these patients. Recruiting --> Active, not recruiting
- || lenvatinib / Generic mfg., celecoxib oral / Generic mfg.
Clinical, Journal, PD(L)-1 Biomarker, IO biomarker: Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma. (Pubmed Central) - Jan 12, 2022
Thus, COX-2 inhibitor could reduce PD-L1 neutrophil and restore T cell cytotoxicity. This may provide a potent addition to lenvatinib.
- || lenvatinib / Generic mfg.
Clinical, Journal: Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma. (Pubmed Central) - Jan 12, 2022
Although patient characteristics at baseline and PD, their response to lenvatinib, and PFS were similar among those groups, patients with an increase in all growth factors had significantly shorter PPS (median PPS was 553, 323, and 316 versus 173 days in groups 1-4 p = 0.032). We revealed that the evaluation of the changes in growth factors during lenvatinib could predict PPS.
- | New P1 trial: Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma (clinicaltrials.gov) - Jan 11, 2022
P1, N=20, Not yet recruiting, Sponsor: Icahn School of Medicine at Mount Sinai
- | Nexavar (sorafenib) / Bayer, Amgen
Journal: MT1JP-mediated miR-24-3p/BCL2L2 axis promotes Lenvatinib resistance in hepatocellular carcinoma cells by inhibiting apoptosis. (Pubmed Central) - Jan 11, 2022
We revealed that the evaluation of the changes in growth factors during lenvatinib could predict PPS. Our results suggest a novel molecular feedback loop between MT1JP and apoptosis signaling in Lenvatinib sensitive HCC cells.
- || Avastin (bevacizumab) / Roche, Nexavar (sorafenib) / Bayer, Amgen
Clinical, Retrospective data, Review: First-Line Systemic Treatment Strategies for Unresectable Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials. (Pubmed Central) - Jan 11, 2022
Sintilimab plus bevacizumab, atezolizumab plus bevacizumab, lenvatinib, and linifanib had better PFS outcomes than sorafenib...Thus, sintilimab plus bevacizumab may be a better first line choice for the treatment of patients with unresectable HCC. PROSPEROI [https://www.crd.york.ac.uk/PROSPERO/index.php], identifier CRD42021269734.
- || Nexavar (sorafenib) / Bayer, Amgen
Clinical, Journal: TACE Plus Lenvatinib Versus TACE Plus Sorafenib for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Prospective Cohort Study. (Pubmed Central) - Jan 11, 2022
In HCC with PVTT, TACE-L was significantly superior to TACE-S with respect to OS, PFS, and ORR. A larger-scale randomized clinical trial is needed.
- |||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial: PRIMER-1: Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - Jan 11, 2022
P2, N=60, Not yet recruiting, Sponsor: University College, London
- | Tevimbra (tislelizumab-jsgr) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment change, Trial completion date, Trial primary completion date: TALENT: Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC (clinicaltrials.gov) - Jan 10, 2022
P2, N=80, Recruiting, Sponsor: Sun Yat-sen University
A larger-scale randomized clinical trial is needed. N=43 --> 80 | Trial completion date: Jun 2022 --> Jun 2023 | Trial primary completion date: Dec 2021 --> Dec 2022
- Nexavar (sorafenib) / Bayer, Amgen
A retrospective single centre study exploring the efficacy of sequential tyrosine kinase inhibitors (TKI) in patients with hepatocellular cancer. (In-Person Only | Level 1, West Hall; Poster Board - C7) - Jan 8, 2022 - Abstract #ASCOGI2022ASCO_GI_792;
Further data is required to explore the impact on quality of life during therapy. Key: SOR = Sorafenib, LEN = Lenvatinib, REG = Regorafenib.
- || lenvatinib / Generic mfg.
Clinical, Retrospective data, Journal: Levocarnitine Supplementation Suppresses Lenvatinib-Related Sarcopenia in Hepatocellular Carcinoma Patients: Results of a Propensity Score Analysis. (Pubmed Central) - Jan 8, 2022
Baseline SMI and changes in baseline SMI after 6 weeks of treatment were significantly correlated with free carnitine levels (r = 0.359, p = 0.037; and r = 0.345, p = 0.045, respectively). Levocarnitine supplementation can suppress sarcopenia progression during lenvatinib therapy.
- || Nexavar (sorafenib) / Bayer, Amgen
Clinical data, Journal: Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy. (Pubmed Central) - Jan 8, 2022
Sorafenib was shown to be correlated with more HFSR, diarrhea and fatigue, while lenvatinib with more hypertension and fatigue. Our study highlighted for the first time the efficacy and safety of lenvatinib in an Italian cohort of patients.
- | Keytruda (pembrolizumab) / Merck (MSD)
Journal, Tumor Mutational Burden, PD(L)-1 Biomarker, IO biomarker: The Lenvatinib/Pembrolizumab combination is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma. (Pubmed Central) - Jan 7, 2022
Our results implicate that the combination of lenvatinib and pembrolizumab might be safe and effective in patients with ATC/PDTC including complete and long-term remissions. The combination treatment is now systematically examined in a phase II clinical trial (Anaplastic Thyroid Carcinoma Lenvatinib Pembrolizumab - ATLEP) in ATC/PDTC patients.
- | Keytruda (pembrolizumab) / Merck (MSD), Avastin (bevacizumab) / Roche
Journal, HEOR: Lenvatinib plus pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis. (Pubmed Central) - Jan 7, 2022
LP is not cost-effective in patients with recurrent pretreated, MSS EC. A dramatic reduction in cost of LP is required for this novel strategy to be cost-effective.
- || paclitaxel / Generic mfg., lenvatinib / Generic mfg.
Clinical, P1 data, Journal: Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer. (Pubmed Central) - Jan 7, 2022
The regimen was tolerable with manageable side effects. Encouraging activity was observed in endometrial and ovarian cancer, and warrants further development.
- | Nexavar (sorafenib) / Bayer, Amgen
Journal: Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells. (Pubmed Central) - Jan 7, 2022
Overall, the findings suggest that the underlying mechanism of lenvatinib in overcoming sorafenib resistance in HCC involves FGFR4-ERK signaling. Lenvatinib may be a suitable second-line therapy for unresectable HCC patients who have developed sorafenib resistance and express FGFR4.
- | Tyvyt (sintilimab) / Eli Lilly
Retrospective data, Journal: The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study. (Pubmed Central) - Jan 7, 2022
Median overall survival (OS) was 23.6 months (95%CI 22.2-25.0 months). TACE combined with lenvatinib plus sintilimab is a promising therapeutic regimen in unresectable hepatocellular carcinoma.
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date: Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC) (clinicaltrials.gov) - Jan 6, 2022
P2, N=60, Active, not recruiting, Sponsor: Academic and Community Cancer Research United
TACE combined with lenvatinib plus sintilimab is a promising therapeutic regimen in unresectable hepatocellular carcinoma. Trial completion date: Sep 2022 --> Sep 2024 | Trial primary completion date: Oct 2021 --> Oct 2022
- || lenvatinib / Generic mfg.
Clinical, Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker: Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers. (Pubmed Central) - Jan 6, 2022
Trial completion date: Sep 2022 --> Sep 2024 | Trial primary completion date: Oct 2021 --> Oct 2022 The CNVs in plasma cfDNA could predict the clinical outcome of the combination therapy of PD-1 inhibitor with lenvatinib and other ICI-based therapies in hepatobiliary cancers.